Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week as it targets a fast-growing diabetes and obesity market where demand for weight-loss treatments is surging.

Global pharmaceutical leaders Eli Lilly and Novo Nordisk are intensifying competition in Indias rapidly expanding obesity drug market as they race to secure dominance before lower-cost generic alternatives arrive in

Canadians face a longer-than-expected wait for cheaper versions of Novo Nordisk A/S’s diabetes drug Ozempic after two of the biggest generics makers were hit with additional requests from the health regulator.

Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week and targeting a booming diabetes and obesity market expected to power industry growth this decade.

In an exclusive interaction with NDTV, Managing Director of Novo Nordisk India, Vikrant Shrotriya, said the launch of injectable semaglutide marks a significant moment for diabetes treatment.

Danish pharmaceutical giant Novo Nordisk has introduced its type 2 diabetes treatment, Ozempic, in India. Positioned as a diabetes medication with weight-loss benefits, this launch aims to cater to an increasing diabetic population.

Novo Nordisk has launched Ozempic in India at ₹2,200 per week, expanding diabetes treatment options even as patent disputes over semaglutide continue in Indian courts.

Bond yields jumped after the report, and the S&P 500 was set to close at a record high.These stocks were moving Tuesday:U.S.-listed shares in Danish drugmaker Novo Nordisk rose 6.5% after the Food and Drug Administration approved the first GLP-1 pill,